Allscripts, Nanthealth team up for personalized cancer care

NantHealth and Allscripts have joined forces to collaborate on the development and delivery of precision medicine solutions directly to the point of care. The companies will introduce an integrated, evidence-based, personalized approach to healthcare solutions that includes actionable clinical data, enabling physicians to make informed decisions from complex genomic and proteomic analysis.

“Our goal is to enable physicians to make better, more informed decisions, provide best-in-class patient care and monitor the effectiveness and progress of treatment, using real-time clinical and panomic data never before available,” said Patrick Soon-Shiong, MD, MS, founder and CEO of NantHealth, in a release. “We look forward to working in partnership with the Allscripts team as the first major clinical EMR vendor to take a major advancement towards the interoperability necessary to enable physicians and patients to stay engaged and active--before, during and after treatment–and enable the most appropriate, personalized intervention as early as possible.”

Research has shown that a physician’s ability to make effective, evidence-based clinical decisions can improve by using specifically matched cancer protocols and drugs, delivered to the patient based on the individual’s unique DNA, RNA and proteomic profile, and integrated with the patient’s holistic clinical picture. NantHealth and Allscripts can integrate these two aspects into a knowledge-based solution to improve cancer treatment.

Beginning with genomic (DNA) and transcriptome (RNA) sequencing, foundational data on how a patient is likely to respond to a specific treatment protocol will integrate with big data and data-mining-based computational analysis. These new NantHealth technologies will enable providers to determine the most accurate treatment option in the complex world of genomically-driven cancer care.

With this comprehensive view of the patient from all data sources, physicians can then use NantHealth’s eviti solution, a comprehensive oncology decision support application that helps select the optimal protocol for patients and verifies their eligibility for it. The eviti platform empowers oncologists with real-time, actionable, evidence-based treatment and clinical trial information to help them make informed treatment decisions for their patients.

NantHealth can gather and monitor patient data via NantHealth’s DeviceConX and Hbox, a medical device data integration solution that works at the point of care for clinicians or at home for the patient. Combined with critical clinical data from the physician’s EMR and community data collected across the continuum of care, clinicians can proactively manage and monitor populations of patients over time and their optimize their treatment. Clinicians can then identify all relevant outcomes, improvements and gaps in care and make them available within the care providers’ workflow in any environment.

Together, physicians and patients will have the tools to stay engaged and active and provide necessary intervention as early as possible. Leveraging innovations in patient engagement, care coordination and disease management, NantHealth and Allscripts are creating the first fully comprehensive and integrated platform that will provide a transformation to the coordination and delivery of cancer care.

“Integrated patient information-–from the molecular level and from the entire continuum of care-–is a powerful tool to improve healthcare,” said Allscripts CEO Paul M. Black.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.